BIOLASE Closes Previously Announced $5 Million Registered Direct Offering
IRVINE, CA -- (Marketwired) -- 09/30/13 -- BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, and a pioneer in laser surgery in other medical specialties,
has closed its previously announced agreement to sell 2,688,172
shares of common stock in a registered direct public offering to a
single investor, Camber Capital Management, LLC ("Camber").
The offering price of $1.86 per share, a price equal to the closing
price on September 23, 2013, resulted in gross proceeds of $5
million, before deducting placement agent commissions of $250,000 and
estimated offering expenses of approximately $100,000.
Northland Securities, Inc. acted as exclusive placement agent in
connection with the offering.
Federico Pignatelli, Chairman and CEO of BIOLASE, said, "We are very
pleased to have completed this financing which, along with the cash
we expect to generate from operations in our 2013 fourth quarter,
will provide us the capital necessary to continue our short-term
growth. Throughout the years, BIOLASE's fourth quarter has
traditionally been its best quarter. We are also excited to add
Camber Capital Management as a high quality, long-term fundamental
investor."
The shares were offered pursuant to a shelf registration statement on
Form S-3 (File No. 333-190158) filed pursuant to the Securities Act
of 1933, as amended, which was previously filed with, and declared
effective by, the Securities and Exchange Commission (the "SEC"). A
prospectus supplement relating to the offering has been filed with
the SEC and can be obtained at the SEC's website at
http://www.sec.gov, at request from Northland Securities, Inc. by
e-mailing Andrew Pafko at apafko@northlandcapitalmarkets.com, or from
BIOLASE, Inc., 4 Cromwell, Irvine, California 92618.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of BIOLASE in this
offering. There shall not be any offer, solicitation of an offer to
buy, or for the sale of securities in any state or jurisdiction in
which such an offering, solicitation, or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction. Any offering will be made only by means
of a prospectus, including a prospectus supplement, forming a part of
the effective registration statement.
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate approximately 315 patented and patent-pending
technologies designed to provide biologically clinically superior
performance with less pain and faster recovery times. Its innovative
products provide cutting-edge technology at competitive prices to
deliver the best results for dentists and patients. BIOLASE's
principal products are revolutionary dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 23,000 lasers. Other laser
products under development address ophthalmology and other medical
and consumer markets.
For updates and information on WaterLase(R) and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos.
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Inc.
Additional Information
Statements made in this press release include
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, regarding, but not limited to, the
amount BIOLASE expects to receive from the offering and the timing
for the closing of the offering. Forward-looking statements can be
identified by the use of words such as "may," "will," "plan,"
"should," "expect," "anticipate," "estimate," "continue," or
comparable terminology. Such forward-looking statements are
inherently subject to certain risks, trends and uncertainties, many
of which BIOLASE cannot predict with accuracy and some of which
BIOLASE might not even anticipate, and involve factors that may cause
actual results to differ materially from those projected or
suggested. These risks and uncertainties include, among others, the
factors described under the Risk Factors section of BIOLASE's Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with
the SEC. BIOLASE cautions investors not to place considerable
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this press release, and
BIOLASE undertakes no obligation to update or revise the statements.
For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.
212-564-4700